Beta-blocker contraindications: persistent
- 14LL. H/O: betablocker allergy
- TJC6. Adverse reaction to betablockers
- TJC61 Adverse reaction to acebutolol
- TJC62 Adverse reaction to atenolol
- TJC63 Adverse reaction to labetalol
- TJC64 Adverse reaction to metoprolol
- TJC65 Adverse reaction to nadolol
- TJC66 Adverse reaction to oxprenolol
- TJC67 Adverse reaction to sotalol
- TJC68 Adverse reaction to timolol
- TJC6z Adverse reaction to betablockers NOS
- U60B7 [X]Beta-adrenoreceptor antagonists causing adverse effects in therapeutic
use, not elsewhere classified
- ZV14C [V]Personal history of betablocker allergy
U60B9 [X]Adverse reaction to bisoprolol (v16)
U60BA [X]Adverse reaction to carvedilol (v16)
U60BB [X]Adverse reaction to nebivolol (v16)
ZVu6i [X]Personal history of allergy to bisoprolol (v16)
ZVu6o [X]Personal history of allergy to carvedilol (v16)
ZVu6q [X]Personal history of allergy to nebivolol (v16)
Beta-blocker contraindications: expiring (Added in the last 15 months)
- 8I26. Beta blocker contraindicated
- 8I36. Beta blocker therapy refused
- 8I62. Beta blocker not indicated
- 8I73. Beta blocker not tolerated
8I2g. Bisoprolol contraindicated (v16)
8I2h. Carvedilol contraindicated (v16)
8I2i. Nebivolol contraindicated (v16)
8I6i. Bisoprolol not indicated (v16)
8I6j. Carvedilol not indicated (v16)
8I6k. Nebivolol not indicated (v16)
8I7K. Bisoprolol not tolerated (v16)
8I7L. Carvedilol not tolerated (v16)
8I7M. Nebivolol not tolerated (v16)
8IAS. Bisoprolol therapy refused (v16)
8IAT. Carvedilol therapy refused (v16)
8IAV. Nebivolol therapy refused (v16)
Beta-blocker prescription codes (Issued in the last 6 months)
bd…%
CHD Diagnosis Codes
- G3... Ischaemic heart disease - G330z Angina decubitus NOS
(Except G30A. Mural thrombosis v17)
- G33z. Angina pectoris NOS - G3401 Double coronary vessel disease
- G342. Atherosclerotic cardiovascular disease - G366. Thrombosis of atrium,
auricular appendage, and ventricle as current complications following acute
myocardial infarction
- G38.. Postoperative myocardial infarction - G3z.. Ischaemic heart disease
NOS
- Gyu3. [X]Ischaemic heart diseases
- Gyu30 [X]Other forms of angina pectoris
- Gyu31 [X]Other current complications following acute myocardial infarction
- Gyu32 [X]Other forms of acute ischaemic heart disease
- Gyu33 [X]Other forms of chronic ischaemic heart disease
- Gyu34 [X]Acute transmural myocardial infarction of unspecified site
- Gyu35 [X]Subsequent myocardial infarction of other sites
- Gyu36 [X]Subsequent myocardial infarction of unspecified site
CHD exception reporting codes (In last 15 months)
- 9h0.. Exception reporting: CHD quality indicators
- 9h01. Excepted from CHD quality indicators: Patient unsuitable
- 9h02. Excepted from CHD quality indicators: Informed dissent
CHD 10.1 Rationale
Long-term beta blockade remains an effective and well-tolerated
treatment that reduces mortality and morbidity in patients with angina and patients
after myocardial infarction.
Although the trial evidence relates mainly to patients who have
had a myocardial infarction, experts have generally extrapolated this evidence
to all patients with CHD.Because the evidence is not based on all patients with
CHD, the target levels for this indicator have been set somewhat lower than
for other process indicators.
Recent evidence against the use of beta blockers in hypertension
should not be extrapolated to patients with CHD.
Grade A Recommendation SIGN Guidelines 96 and 97 (2007)
Further information: www.sign.ac.uk/guidelines/fulltext/96/index.html
CHD 10.2 Reporting and verification
The percentage of patients on the CHD register who have been prescribed
a beta blocker in the preceding six months.
Prepared By Jean Keenan